β1-adrenergic and Muscarinic Acetylcholine Type 2 Receptor Antibodies are Increased in Graves’ Hyperthyroidism and Decrease During Antithyroid Therapy
- 12 January 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 129 (11), 783-790
- https://doi.org/10.1055/a-1342-2853
Abstract
Objective To determine the association between autoantibodies to G-protein-coupled receptors with effect on the cardiovascular system and the cardiac biomarker N-terminal pro-brain natriuretic peptide reflecting heart function in Gravesʼ disease. Design and Methods Sixty premenopausal women with Graves’ disease were analyzed for IgG autoantibodies against β1-adrenergic, muscarinic acetylcholine type 2 and angiotensin II type 1 receptors using enzyme-linked immunosorbent assays based on cell membranes overexpressing receptors in their native conformations. N-terminal pro-brain natriuretic peptide and heart symptoms were analyzed in hyperthyroidism and after 7.5 months of antithyroid treatment. Matched thyroid healthy controls were also assessed. Results Serum levels of antibodies against the β1-adrenergic and the muscarinic acetylcholine type 2 receptors were higher in hyperthyroid patients than in controls (median β1-adrenergic receptor antibodies 1.9 [IQR 1.3–2.7] vs. 1.1 [0.8–1.7] μg/mL, P1-adrenergic and the muscarinic acetylcholine type 2 receptors were increased in Graves’ patients, decreased with treatment, but did not correlate with cardiac function. However, an autoimmune effect on the heart cannot be excluded in subpopulations, as the functional properties of the analyzed antibodies remain to be determined. Received: 28 September 2020 Received: 02 December 2020 Accepted: 22 December 2020 Publication Date: 12 January 2021 (online) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 39 references indexed in Scilit:
- Receptor-activating autoantibodies and disease: preeclampsia and beyondExpert Review of Clinical Immunology, 2011
- Activating Autoantibodies to the Beta-1 Adrenergic and M2 Muscarinic Receptors Facilitate Atrial Fibrillation in Patients With Graves' HyperthyroidismJournal of Invasive Cardiology, 2009
- Altered cardiovascular vagal responses in nonelderly female patients with subclinical hyperthyroidism and no apparent cardiovascular diseaseClinical Endocrinology, 2007
- N-Terminal-Pro-B-type Natriuretic Peptide in Acute HyperthyroidismThyroid®, 2007
- Hyperthyroidism affects arterial stiffness, plasma NT‐pro‐B‐type natriuretic peptide levels, and subendocardial perfusion in patients with Graves' diseaseAnnals of Medicine, 2007
- Triiodothyronine Increases Brain Natriuretic Peptide (BNP) Gene Transcription and Amplifies Endothelin-dependent BNP Gene Transcription and Hypertrophy in Neonatal Rat Ventricular MyocytesOnline Journal of Public Health Informatics, 2003
- Graves' Disease and Low-Output Cardiac Dysfunction: Implications for Autoimmune Disease in Endomyocardial Biopsy Tissue from Eleven PatientsThyroid®, 2000
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997
- Autoantibodies against Cardiac G-Protein-Coupled Receptors Define Different Populations with Cardiomyopathies but Not with HypertensionClinical Immunology and Immunopathology, 1994
- Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardiaJournal of Invasive Cardiology, 1990